Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIGA-564 in Advanced Solid Tumors
NCT06258304Phase 1Recruiting
- Sponsor
- GigaGen Inc.
- Start
- May 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GIGA-564 in solid tumor (2 arms), sponsored by GigaGen Inc. Primary endpoints: Treatment-emergent Adverse Events up to 154 days, Grade 3 or 4 Treatment-emergent Adverse Events up to 154 days and 4 more. Started May 2024; status: recruiting.
02
Drugs
GIGA-564
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06258304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258304.